Day One Biopharmaceuticals, Inc. DAWN NASDAQ

Day One Biopharmaceuticals, Inc. (DAWN) reported revenue of $158M in its most recent fiscal year. The company reported a net loss of $107M in its most recent fiscal year, with earnings trending at -2%/yr. The net profit margin is -67.8%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 89.1% (high), with a -6.9pp trend over the period. With a $2B market cap and MOAT composite score of 55/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (58/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 7-year history, the company was profitable in 0 of 7 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (55/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.